Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

54.13
-0.9000-1.64%
Post-market: 54.08-0.0500-0.09%19:30 EDT
Volume:4.35M
Turnover:236.22M
Market Cap:10.40B
PE:30.07
High:55.71
Open:54.86
Low:53.76
Close:55.03
52wk High:73.18
52wk Low:50.76
Shares:192.11M
Float Shares:178.10M
Volume Ratio:1.98
T/O Rate:2.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.80
EPS(LYR):1.80
ROE:5.94%
ROA:5.58%
PB:1.71
PE(LYR):30.07

Loading ...

Wells Fargo says buy BioMarin shares amid Phase 2 trial discontinuation weakness

TIPRANKS
·
Mar 17

BioMarin halts Phase 2 VOXZOGO dosing and enrollment in Turner syndrome, SHOX-deficiency and ACAN-deficiency trials

Reuters
·
Mar 16

Biomarin: Decision to Discontinue Following Occurrence of Several Slipped Capital Femoral Epiphysis Events in 2 Ongoing Investigator-Sponsored Trials

THOMSON REUTERS
·
Mar 16

Biomarin Pharmaceutical - Phase 2 Canopy Trials of Voxzogo in Noonan Syndrome, Idiopathic Short Stature to Continue - SEC Filing

THOMSON REUTERS
·
Mar 16

BioMarin reports VOXZOGO trial data showing 4.7 cm additional height gain at four years in children with achondroplasia treated before age 2

Reuters
·
Mar 12

BioMarin Pharmaceutical Is Maintained at Buy by B of A Securities

Dow Jones
·
Mar 11

Biomarin Pharmaceutical Inc : Bofa Global Research Cuts Price Objective to $85.00 From $97.00

THOMSON REUTERS
·
Mar 11

BioMarin price target lowered to $85 from $97 at BofA

TIPRANKS
·
Mar 11

U.S. RESEARCH ROUNDUP-Howmet Aerospace, Nike, Oracle

Reuters
·
Mar 11

PALYNZIQ Pediatric Label Expansion Under REMS Might Change The Case For Investing In BioMarin (BMRN)

Simply Wall St.
·
Mar 11

Absci names Ransi Somaratne chief medical officer as Andreas Busch set to retire

Reuters
·
Mar 07

Camp4 Therapeutics FY 2025 research and collaboration revenue rises 436.5% to USD 3.5 million

Reuters
·
Mar 06

BioMarin Pharmaceutical Is Maintained at Overweight by Barclays

Dow Jones
·
Mar 04

U.S. RESEARCH ROUNDUP-CrowdStrike, Oracle, Vulcan Materials

Reuters
·
Mar 04

Amicus Therapeutics Inc. Held Special Stockholder Meeting

Reuters
·
Mar 04

Cantor Fitzgerald Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Mar 02

H.C. Wainwright Remains a Hold on BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Mar 02

BioMarin Pharmaceutical Price Target Maintained With a $55.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 02

BioMarin Says US FDA Approves Application for Rare Metabolic Disorder Treatment in Adolescents

MT Newswires Live
·
Mar 02

BioMarin announces U.S FDA approved sBLA for Palynziq

TIPRANKS
·
Mar 02